Balu Vijayan, Assistant Professor of Department of Radiation Oncology at Sree Mookambika Institute of Medical Sciences, shared a post on LinkedIn:
“Grateful to have participated as a radiation oncologist in the Trivandrum Oncology Club‘s insightful case discussion on Carcinoma of the Gastroesophageal Junction (GEJ). Thank you to the organizers, fellow panelists, and attendees for the engaging multidisciplinary dialogue that advances upper GI cancer care.
Key points from my perspective: While ESOPEC trial favors perioperative FLOT over CROSS for superior OS in GEJ adenocarcinoma (66 vs 37 months median), neoadjuvant chemoradiation (nCRT) like CROSS retains value for locoregional control (4% vs 8% isolated failure), especially in bulky nodal disease, squamous histology, or poor chemo tolerance. Adjuvant immunotherapy (e.g., Checkmate 577) further bolsters nCRT.”
More post featuring GEJ Cancer on OncoDaily.
